Naoto Ueno
Medical Oncology · Honolulu, HINPI 1851497770
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Chugai Pharmaceutical Co., Ltd. at 30.4% of the total.
Across 175 payments — averaging $1646.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chugai Pharmaceutical Co., Ltd.$88K
- Kyowa Kirin Co., Ltd$68K
- Daiichi Sankyo Inc.$28K
- Lilly USA, LLC$26K
- Daiichi Sankyo Company LTD$19K
- Sysmex America, Inc.$10K
- plus $50K from 23 others
Across 179 payments — averaging $46,445 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.9M
- Daiichi Sankyo Inc.$1.3M
- Novartis$1.1M
- Amgen$976K
- Daiichi Sankyo Company LTD$819K
- Merck Kgaa$371K
- plus $837K from 6 others
What the payments were for
- Consulting fees$113,04239%
- Speaking & faculty fees$12,8184%
- Travel & lodging$158,46755%
- Food & beverage$3,7201%
- Education$600%
- Gifts$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chugai Pharmaceutical Co., Ltd. | 30 | $87,539 |
| Kyowa Kirin Co., Ltd | 47 | $67,777 |
| Daiichi Sankyo Inc. | 10 | $28,138 |
| Lilly USA, LLC | 5 | $26,158 |
| Daiichi Sankyo Company LTD | 2 | $18,525 |
| Sysmex America, Inc. | 19 | $9,590 |
| Sumitomo Pharma Co., Ltd. | 7 | $8,601 |
| AstraZeneca | 7 | $5,811 |
| Pfizer | 5 | $5,351 |
| Gilead | 14 | $5,128 |
| Eisai CO., LTD. | 1 | $3,594 |
| Amgen | 2 | $3,395 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,160 |
| Takeda Pharmaceutical Company, Limited | 1 | $2,160 |
| Immunomedics, Inc. | 1 | $2,100 |
| Eisai Inc. | 1 | $2,031 |
| Bayer | 2 | $2,000 |
| E.r. Squibb & Sons, L.L.C. | 2 | $1,985 |
| Genentech USA, Inc. | 2 | $1,899 |
| Taiho Oncology, Inc. | 3 | $1,684 |
| Telix Pharmaceuticals | 1 | $1,500 |
| Caris MPI, Inc. | 2 | $313 |
| Novartis | 3 | $251 |
| Janssen Scientific Affairs, LLC | 1 | $145 |
| Astrazeneca UK Limited | 1 | $135 |
| Novocure Inc. | 1 | $54 |
| Genentech, Inc. | 2 | $45 |
| Puma Biotechnology, Inc. | 1 | $37 |
| Accord Healthcare, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few medical oncology providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Other medical oncology in Honolulu
- Jami FukuiHonolulu$17K
- Shaun DoneganHonolulu$17K
- Clayton ChanHonolulu$2K
- Clayton ChongHonolulu$2K
- Charles MillerHonolulu$326
- Reuben GuerreroHonolulu$35
- Kevin LohHonolulu$31
- Kitty VictoriaKealakekua$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.